
Deferiprone tablets
Form: Tablet
Strength: 250 mg, 500 mg
Reference Brands: Ferriprox(US)
Category: Blood Disorder
Deferiprone tablets, marketed as Ferriprox, are approved in the EU and US for treating iron overload, particularly in thalassemia patients. Regulatory approval requires a comprehensive dossier including clinical trial data, safety, efficacy, manufacturing standards, and pharmacovigilance plans. In the US, approval is granted by the FDA after rigorous review, while in the EU, EMA guidelines ensure compliance with regional standards. For expert guidance on dossier preparation, regulatory pathways, and successful market entry, visit PharmaTradz. Ensuring regulatory compliance is essential for the safe, effective, and timely approval of deferiprone tablets, supporting better patient management worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Anti-Inhibitor Coagulant Complex (AICC) Lyophilized Powder
Strength: 500 units, 1000 units, and 2500 units
Form: Lyophilized Powder (Reconstituted for IV infusion)
Reference Brands: FEIBA(US)
View Details Get EnquiryProthrombin Complex Concentrate (PCC) injection
Strength: 250 IU to 300 IU
Form: Injection
Reference Brands: Kcentra (4-factor PCC), Bebulin VH (3-factor PCC)(US)
View Details Get EnquiryMesna Injection
Strength: 100 mg/mL
Form: Injection
Reference Brands: Mesnex(US)
View Details Get EnquiryLeucovorin tablets/Capsule
Strength: 15 mg, 50 mg
Form: Tablet/Capsules
Reference Brands: Folvite(US & EU)
View Details Get Enquiry